Dutch biotech Kiadis Pharma appointed Ray Barlow as chief business officer. Barlow most recently led UK-based data-driven drug discovery company E-therapeutics as its CEO. His prior roles include serving at Amgen (NASDAQ: [[ticker:AMGN]]) as executive director of corporate development and at Crucell Vaccines, a Netherlands-based company that’s now a subsidiary of Johnson & Johnson (NASDAQ: [[ticker:JNJ]]).
Kiadis, a clinical-stage firm, is developing cell therapies based on natural killer cells to treat cancers.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
